Radiocobalt theranostic applications: current landscape, challenges, and future directions

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Oncology

Background:

• Radiocobalt isotopes offer dual capabilities for diagnostic imaging and targeted radionuclide therapy.
• Cobalt's unique coordination chemistry facilitates stable complexation with chelators for enhanced in vivo stability and targeting.
• Personalized cancer management can be improved by using imaging to guide and predict therapeutic outcomes.

Purpose of the Study:

• To provide an overview of recent advancements in radiocobalt isotopes for theranostics.
• To focus on the production, chelation chemistry, and in vivo targeting of 55Co and 58mCo-labeled radiopharmaceuticals.
• To highlight the growing role of radiocobalt theranostics in precision oncology.

Main Methods:

• Review of recent developments in radiolabeling techniques.
• Analysis of chelator design for radiopharmaceuticals.
• Evaluation of preclinical data on pharmacokinetic profiles and tumor specificity.

Main Results:

• 55Co and 58mCo serve as a matched pair for PET imaging and Auger electron therapy, respectively.
• Advancements in techniques have improved in vivo stability and tumor specificity of radiocobalt agents.
• Radiocobalt theranostics show promise for personalized cancer management.

Conclusions:

• Radiocobalt theranostics represent a promising platform for precision oncology.
• Further research is needed to address challenges in production scalability, dosimetry, and clinical translation.
• The trajectory suggests a significant future role for radiocobalt-based theranostics in cancer care.